The IPO market is booming in 2026, but who is at the front of the line might surprise you
If you have been following the financial market closely and expected to see a lineup of tech startups knocking on the SEC’s door to go public, the current landscape might catch you off guard. The year 2026 has opened a powerful window of opportunity for initial public offerings, but the main characters in this race are not exactly who you would expect.
With the S&P 500 and Nasdaq hitting all-time highs last week, macroeconomic conditions stabilizing, and volatility pulling back consistently, the environment has become inviting enough for many companies that were simply waiting for the right moment. According to data from Renaissance Capital, 79 IPO filings have already been recorded in the United States in 2026, with 41 pricings at market capitalizations of at least 50 million dollars.
But the most interesting detail of this entire season is exactly who is taking advantage of this window. It is not the big techs or the software startups that dominated previous cycles. It is biotech and healthcare companies that are coming in full force, raising hundreds of millions of dollars and getting even the most cautious bankers in the industry excited.
And hovering over all of it, like a cloud that is impossible to ignore, is SpaceX — with an IPO that could become the largest in human history. 🚀
The question investors, analysts, and entrepreneurs are asking right now is simple: what comes first, what comes next, and who is going to come out on top when this story is over?
Biotech and healthcare: the unexpected stars of the 2026 IPO season
If you have been following the financial market for a while, you know that IPO windows are cyclical and, when they truly open up, companies rush to get in before the wind shifts. What is happening right now, though, looks different from the last few seasons. The biotech and healthcare sector did not just wake up early — it was the first to knock on the investment banks’ doors and is already walking out with fat checks in hand.
Companies focused on obesity therapies, precision oncology, diagnostics powered by artificial intelligence, and digital health platforms are dominating the IPO pipeline with a speed that few analysts anticipated at the end of 2025.
One of the most notable examples is Kailera Therapeutics, an obesity drug developer backed by Atlas Venture and Bain Capital Life Sciences. The company just raised 625 million dollars in an upsized IPO, a clear sign that investor demand exceeded initial expectations. Beyond Kailera, companies like Odyssey Therapeutics and Mobia Medical have also put their plans to go public into motion this month. And X-Energy, the Amazon-backed nuclear energy company, was scheduled to begin trading on the stock exchange last Friday.
The movement makes sense when you look at the numbers up close. The healthcare sector spent the last two years consolidating technologies developed during the pandemic, maturing clinical pipelines, and most importantly, capturing the attention of institutional funds looking for growth with some degree of resilience. When interest rates started to ease and risk appetite began to grow again, these companies were already ready.
While many pure-play tech startups were still adjusting valuations and negotiating with investors over more reasonable multiples, biotechs hit the market with solid clinical data, established strategic partnerships, and a growth narrative that investors could understand — and buy into.
Receive the best innovation content in your email.
All the news, tips, trends, and resources you're looking for, delivered to your inbox.
By subscribing to the newsletter, you agree to receive communications from Método Viral. We are committed to always protecting and respecting your privacy.
Another factor driving the sector was the acceleration of artificial intelligence use within drug development and clinical protocols. Companies that were able to demonstrate how AI reduces the time and cost of clinical research started being viewed in a whole new light by fund managers. This transformed the biotech IPO into something that goes beyond the traditional bet on regulatory approvals. Today, part of the investment thesis is built around the technology platform behind the product — and that broadens the appeal to a much larger pool of investors.
The cascade effect that has bankers buzzing
One of the most interesting dynamics of this IPO cycle is the so-called cascade effect. When the first companies go public and their stock prices hold steady or climb in the days that follow, it sends a positive signal to every other company waiting in line for its turn.
Michael Ewens, a finance professor at Columbia Business School, described this phenomenon pretty directly. According to him, what is happening is that some companies went first, the bankers got excited, and other companies looked at the results and figured the path was clear. There is a kind of collective validation underway — each successful IPO gives confidence to the next one.
This behavior is not exactly new in the capital markets, but the speed at which it is happening in 2026 is turning heads. Recent IPOs with stock prices that held up after their debut are acting like a beacon for issuers that were on the fence. And this is creating a positive feedback loop that, as long as the broader market keeps cooperating, could keep the pipeline of new offerings active longer than expected.
What is driving the market right now
To understand why the IPO market is heating up now and not six months ago, you have to look at the macro environment honestly. The Federal Reserve signaled a more stable stance on interest rates, which reduced the uncertainty that paralyzed many offerings throughout 2024. With the cost of money being more predictable, companies can set valuations with greater confidence, and investors can model returns with fewer variables in play.
That balance, as fragile as it may seem, was enough to unlock a wave of processes that had been bottled up for months in the offices of lead underwriters.
Beyond the interest rate picture, the consistent performance of the S&P 500 and Nasdaq created an important psychological effect: when the indexes are rising, the perception of risk drops and the willingness to participate in new assets increases. Fund managers who had been parked in more defensive positions started looking for exposure to growth stories, and the biotech and healthcare pipeline showed up at exactly the right moment to fill that demand. It is not a coincidence — it is market timing working the way it should.
There is also a generational component worth mentioning. A new generation of investors, far more familiar with science, technology, and data than previous ones, is actively participating in the market. These investors understand biotech bets better, can follow clinical trial results closely, and are not afraid to allocate capital to companies still in their growth phase. This creates a broader demand base for these IPOs, which is reflected in strong subscriptions and above-range pricing in many of the recent offerings.
Why are the big techs sitting this one out?
If the environment is so favorable, why are the major venture-capital-backed technology companies not rushing to go public as well? The answer involves a combination of factors that goes beyond simple market sentiment.
Kyle Stanford, US venture capital research director at PitchBook, offers a revealing perspective on the matter. According to him, the top VC-backed tech companies may have valuations that are too high to find support in the public stock market with business models that are not yet profitable. In other words, there is a disconnect between what these companies are worth in the private market and what public investors are willing to pay for them.
And the problem does not stop there. Stanford also noted that even tech companies that were turning a profit when they went public recently have not performed particularly well on the stock exchange. This created a chilling effect for other tech firms that were considering following the same path. If even the profitable ones are not doing well, imagine those still burning cash.
This scenario helps explain why new listings are concentrated in biotech, healthcare, and mature companies backed by private equity. These are profiles that the public market can price more comfortably right now — whether because of the visibility of clinical data, in the case of biotechs, or the predictability of revenue and margins, in the case of more mature companies.
SpaceX: the IPO everyone is waiting for, but nobody knows when it will happen
And then there is SpaceX. Talking about IPOs in 2026 without mentioning Elon Musk’s company is practically impossible — not because it has confirmed any date or given any concrete signal, but precisely the opposite. The absence of information has become the story itself.
SpaceX is, at this moment, the biggest elephant in the room of the global capital market, and everyone is waiting to see when — and if — it will walk through the front door.
The numbers floating around about SpaceX are dizzying. With a valuation surpassing hundreds of billions of dollars in recent secondary transactions, the company would already be, on its own, larger than most publicly listed companies in the world. An IPO at that level would not just be the biggest of the year — it would be one of the largest in the recent history of global markets.
Steve Brotman, managing partner at Alpha Partners, a late-stage investment firm, summed up the sentiment among smaller issuers regarding SpaceX pretty well. According to him, if you are a smaller issuer, you want to get out before that truck comes down the road. Nobody knows how much money is going to be left on the table. We are talking about one of the largest IPOs in human history.
The projections are ambitious: SpaceX, along with Anthropic and OpenAI, has the potential to deliver the biggest year in IPO fundraising ever, potentially generating more exit value than all venture-capital-backed IPOs since the year 2000 combined. It is a number so large it sounds like an exaggeration, but analysts are taking this possibility seriously. 🛰️
At the same time, SpaceX has deliberately stayed out of the public market spotlight. The company continues to raise capital through private rounds, maintains a loyal base of institutional investors, and operates with a strategic freedom that would be much harder to preserve under the pressure of quarterly earnings and Wall Street analyst expectations.
The SpaceX effect on the rest of the market
There is an interesting discussion about how a potential SpaceX IPO could impact the market as a whole. Lisa Buyer, co-founder of IPO advisory group Class V Group, offered two complementary perspectives on the topic.
On one hand, if SpaceX has a sustainably positive debut on the stock exchange, it could open the door for other technology companies — perhaps artificial intelligence companies beyond the mega-caps — to try to ride a market perceived as friendly to new listings.
On the other hand, Buyer also points out that there is a lot of speculation and noise surrounding SpaceX, and that probably no potential issuer is really altering its plans because of it. What truly matters, according to her, is overall market performance and the individual growth of each company that will determine if and when they decide to go public.
This is an important take because it brings the focus back to fundamentals: at the end of the day, every company needs to have its own solid investment thesis, regardless of what SpaceX does or does not do.
Who comes out ahead in this race?
The most honest answer is: it depends on where you are positioned and what your investment horizon looks like. For investors who got in early on this year’s biotech and healthcare offerings, the initial returns have been quite encouraging. But the sector’s track record teaches us that long-term stock performance depends far more on clinical results than on the excitement of IPO day.
A company that goes public with a compelling story and then fails a phase three trial can lose 60%, 70% of its value in a matter of days. The biotech market is generous with those who get it right, but it does not forgive mistakes easily.
For those eyeing SpaceX, the horizon is completely different. There is no confirmed IPO, no date, no prospectus. What exists is a company that is growing organically and that, if and when it decides to go public, will create massive demand in a very short period of time. Preparing for that event means closely tracking the company’s moves, understanding the business structure — especially Starlink — and having clarity on your investment thesis before the frenzy takes over rational analysis.
What is clear is that the IPO market in 2026 is writing a different story than the ones before it. Biotech and healthcare have shown that resilience and solid data are worth just as much as explosive revenue growth when the environment is right. Pure-play tech companies, for now, continue watching from the sidelines, waiting for clearer signals that the public market will welcome them with the same enthusiasm it showed in past cycles.
And SpaceX remains the chapter everyone wants to read, but that has not been written yet. In the meantime, the market stays hot, the bankers stay busy, and investors stay alert — because in windows like this one, if you blink, you might miss your turn. 👀
